Abstract
Norfloxacin has some activity in vitro against Chlamydia trachomatis and Ureaplasma urealyticum, although not at levels attainable in serum. In this study, norfloxacin was administered (400 mg orally twice daily for 10 days) to men with acute nongonococcal urethritis. Of 25 men from whom C. trachomatis was initially isolated, 21 had the organism reisolated at the first follow-up visit posttreatment, and there were minimal changes in the number of inclusion-forming units in culture. Ultimately, all but 1 of the 22 men from whom C. trachomatis was initially isolated and who were monitored became clinical failures within 42 +/- 7 days posttreatment. The clinical outcome was significantly better for men from whom U. urealyticum was initially isolated but from whom C. trachomatis was not isolated. Of 27 men, 17 became and stayed culture negative for U. urealyticum at follow-ups, and clinically, 15 no longer had nongonococcal urethritis. Of these 15, all 12 monitored until at least 42 +/- 7 days posttreatment remained improved. Of 26 men from whom neither C. trachomatis nor U. urealyticum was initially isolated, 18 improved and all 15 who were monitored until at least 42 +/- 7 days posttreatment remained improved. Thus, although norfloxacin attains high levels in urine and has good tissue penetration, it had essentially no activity against chlamydial urethritis in men. It had better, but incomplete, activity against U. urealyticum. For quinolones to show promise in vivo against C. trachomatis, either the MICs will need to be much lower or the levels attained in serum will have to be much higher.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aznar J., Caballero M. C., Lozano M. C., de Miguel C., Palomares J. C., Perea E. J. Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother. 1985 Jan;27(1):76–78. doi: 10.1128/aac.27.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bowie W. R., Jones H. Acute pelvic inflammatory disease in outpatients: association with Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med. 1981 Dec;95(6):685–688. doi: 10.7326/0003-4819-95-6-685. [DOI] [PubMed] [Google Scholar]
- Bowie W. R., Yu J. S., Fawcett A., Jones H. D. Tetracycline in nongonococcal urethritis. Comparison of 2 g and 1 g daily for seven days. Br J Vener Dis. 1980 Oct;56(5):332–336. doi: 10.1136/sti.56.5.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crider S. R., Colby S. D., Miller L. K., Harrison W. O., Kerbs S. B., Berg S. W. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med. 1984 Jul 19;311(3):137–140. doi: 10.1056/NEJM198407193110301. [DOI] [PubMed] [Google Scholar]
- Heessen F. W., Muytjens H. L. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis. Antimicrob Agents Chemother. 1984 Jan;25(1):123–124. doi: 10.1128/aac.25.1.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heppleston C., Richmond S., Bailey J. Antichlamydial activity of quinolone carboxylic acids. J Antimicrob Chemother. 1985 May;15(5):645–647. doi: 10.1093/jac/15.5.645. [DOI] [PubMed] [Google Scholar]
- Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meier-Ewert H., Weil G., Millott G. In vitro activity of norfloxacin against Chlamydia trachomatis. Eur J Clin Microbiol. 1983 Jun;2(3):271–272. doi: 10.1007/BF02029532. [DOI] [PubMed] [Google Scholar]
- Ridgway G. L., Mumtaz G., Gabriel F. G., Oriel J. D. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. Eur J Clin Microbiol. 1984 Aug;3(4):344–346. doi: 10.1007/BF01977491. [DOI] [PubMed] [Google Scholar]
- Shepard M. C., Lunceford C. D. Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T mycoplasmas) in primary cultures of clinical material. J Clin Microbiol. 1976 Jun;3(6):613–625. doi: 10.1128/jcm.3.6.613-625.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shepard M. C., Lunceford C. D. Urease color test medium U-9 for the detection and identification of "T" mycoplasms in clinical material. Appl Microbiol. 1970 Oct;20(4):539–543. doi: 10.1128/am.20.4.539-543.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Roosbroeck R. J., Provinciael D. R., Van Caekenberghe D. L. Activity of the newer quinolones against Chlamydia trachomatis. Br J Vener Dis. 1984 Oct;60(5):350–350. doi: 10.1136/sti.60.5.350. [DOI] [PMC free article] [PubMed] [Google Scholar]